Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)
Phase 2
Withdrawn
- Conditions
- Venous Thromboembolism
- Registration Number
- NCT00541320
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study was designed to assess the safety and efficacy of GW813893 in the prophylaxis of VTE following TKR and to provide evidence to enable the selection of the appropriate dose(s) and dose regimen of GW813893 for future investigation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Incidence of death OR symptomatic or non-symptomatic blood clots in the legs OR symptomatic blood clots in the lungs within 7 +/- 2 days following total knee replacement surgery. symptomatic blood clots in the lungs within 7 +/- 2 days following total knee replacement surgery.
- Secondary Outcome Measures
Name Time Method Incidence of bleeding within 7 +/- 2 days following total knee replacement surgery. Incidence of bleeding within 7 +/- 2 days following total knee replacement surgery
Trial Locations
- Locations (2)
GSK Clinical Trials Call Center'
🇺🇸Phoenix, Arizona, United States
GSK Clinical Trials Call Center
🇺🇸San Antonio, Texas, United States